
UCB SA – OTC:UCBJY
UCB SA stock price today
UCB SA stock price monthly change
UCB SA stock price quarterly change
UCB SA stock price yearly change
UCB SA key metrics
Market Cap | 15.93B |
Enterprise value | 39.15B |
P/E | 73.82 |
EV/Sales | 5.77 |
EV/EBITDA | 26.69 |
Price/Sales | 5.38 |
Price/Book | 2.11 |
PEG ratio | 1.20 |
EPS | 2.69 |
Revenue | 7.84B |
EBITDA | 1.98B |
Income | 514.5M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 3.77% |
Oper. margin | 8.59% |
Gross margin | 65.92% |
EBIT margin | 8.59% |
EBITDA margin | 25.25% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUCB SA stock price history
UCB SA stock forecast
UCB SA financial statements
Mar 2023 | 1.25B | 155.5M | 12.35% |
---|---|---|---|
Jun 2023 | 2.58B | 311M | 12.01% |
Sep 2023 | 1.33B | 16M | 1.2% |
Dec 2023 | 2.66B | 32M | 1.2% |
2025 | 6.92B | 660.51M | 9.54% |
---|---|---|---|
2026 | 7.71B | 855.15M | 11.08% |
2027 | 8.48B | 1.04B | 12.35% |
2028 | 9.10B | 1.22B | 13.42% |
Analysts Price target
Financials & Ratios estimates
Paying a dividend greater than earnings.
Payout ratio | 101.17% |
---|
2019 | 3.38% |
---|---|
2020 | 2.83% |
2021 | 2.54% |
2022 | 3.55% |
2023 | 3.3% |
Mar 2023 | 15382000000 | 6.34B | 41.22% |
---|---|---|---|
Jun 2023 | 15382000000 | 6.33B | 41.21% |
Sep 2023 | 15539000000 | 6.56B | 42.24% |
Dec 2023 | 15539000000 | 6.56B | 42.24% |
Mar 2023 | 124.5M | -136.5M | -183.5M |
---|---|---|---|
Jun 2023 | 148M | -273M | -266M |
Sep 2023 | 256M | -83.5M | 29.5M |
Dec 2023 | 469M | -167M | 102M |
UCB SA alternative data
Aug 2023 | 8,108 |
---|---|
Sep 2023 | 8,600 |
Oct 2023 | 8,600 |
Nov 2023 | 8,600 |
Dec 2023 | 8,600 |
Jan 2024 | 8,600 |
Feb 2024 | 8,600 |
Mar 2024 | 8,450 |
Apr 2024 | 8,450 |
May 2024 | 8,450 |
Jun 2024 | 8,450 |
Jul 2024 | 8,450 |
UCB SA other data
Amgen: Imdelltra Data And Q1 Results Impress
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Uncertainty Looms Over Immunovant's Future As Batoclimab Faces Dim Prospects
Argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important
Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating
Galapagos: Can The Company Turn Around?
-
What's the price of UCB SA stock today?
One share of UCB SA stock can currently be purchased for approximately $112.2.
-
When is UCB SA's next earnings date?
Unfortunately, UCB SA's (UCBJY) next earnings date is currently unknown.
-
Does UCB SA pay dividends?
Yes, UCB SA pays dividends and its trailing 12-month yield is 0.48% with 101% payout ratio.It means that the company is paying a dividend greater than earnings. The last UCB SA stock dividend of undefined was paid on 4 Sep 2025.
-
How much money does UCB SA make?
UCB SA has a market capitalization of 15.93B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.8% to 5.25B US dollars.
-
What is UCB SA's stock symbol?
UCB SA is traded on the OTC under the ticker symbol "UCBJY".
-
What is UCB SA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of UCB SA?
Shares of UCB SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does UCB SA have?
As Jul 2024, UCB SA employs 8,450 workers.
-
When UCB SA went public?
UCB SA is publicly traded company for more then 6 years since IPO on 30 Nov 2018.
-
What is UCB SA's official website?
The official website for UCB SA is ucb.com.
-
How can i contact UCB SA?
UCB SA can be reached via phone at +32 2 559 99 99.
UCB SA company profile:

UCB SA
ucb.comOTC
8,600
Biotechnology
Healthcare
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Brussels, 1070
:
ISIN: US9034801012
CUSIP: 903480101